セッション

Bosutinib vs Imatinib for newly diagnosed chronic myeloid leukemia (CML): Results of the BFORE trial

[演者] Jorge E. Cortes:1
[著者] Carlo Gambacorti-Passerini:2, Michael Deininger:3, Michael J. Mauro:4, Thuan Heng Charles Chuah:5, Dong-Wook Kim:6, Laurence Reilly:7, Allison Jeynes-Ellis:7, Eric Leip:8, Nathalie Bardy-Bouxin:9, Andreas Hochhaus:10, Tim H. Brummendorf:11, on behalf of the BFORE Study Investigators
1:University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2:University of Milano-Bicocca, Monza, IT, 3:University of Utah, Salt Lake City, UT, USA, 4:Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5:Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore, SG, 6:Seoul St. Marys Hospital, Seoul, KR, 7:Avillion LLP, London, UK, 8:Pfizer Inc., Cambridge, MA, USA, 9:Pfizer Global Research and Development, Paris, FR, 10:Klinik für Innere Medizin II, Universitatsklinikum Jena, Jena, DE, 11:Universitatsklinikum RWTH Aachen, Aachen, DE

DMR and TFR following 2-year consolidation by Nilotinib in patients with CML: STAT trial in Japan

[演者] Naoto Takahashi (高橋 直人):1
[著者] Chiaki Nakaseko (中世古 知昭):2, Kaichi Nishiwaki (西脇 嘉一):3, Hisashi Wakita (脇田 久):4, Michihide Tokuhira (得平 道英):5, Jun Kuroki (黒木 淳):6, Hideo Kimura (木村 英夫):7, Kohshi Ohishi (大石 晃嗣):8, Hideyoshi Noji (野地 秀義):9, Kinuko Mitani (三谷 絹子):10, Hitoshi Ogasawara (小笠原 仁):11, Masaaki Noguchi (野口 雅章):12, Hiroshi Handa (半田 寛):13, Kazuhisa Fujikawa (藤川 一寿):14, Osamu Iwase (岩瀬 理):15, Fumihiko Kimura (木村 文彦):16, Masatomo Miura (三浦 昌朋):17
1:Hematol., Akita Univ., Akita, Japan, 2:Hemato., Chiba Univ., Chiba, Japan, 3:Oncology and Hematol., Jikei Univ. Kashiwa Hosp., Kashiwa, 4:Hematol. and Oncology, Japanese Red Cross Narita Hosp., Narita, 5:Hematol., Saitama Medical Univ., Kawagoe, 6:Intl. Med., Yuri General Hospital, Yurihonjo, 7:Hematology, Northern Fukushima Medical Center, Date, 8:Transfusion Service, Mie University Hospital, Tsu, 9:Med. Oncol./ Hematol., Fukushima Medical University, Fukushima, 10:Hematol. and Oncol., Dokkyo Medical University, Mibu-machi, 11:Hematol. and Oncol., Odate Municipal Hospital, Odate, 12:Hematol., Juntendo Univ. Urayasu Hosp., Urayasu, 13:Hematol., Gunma Univ. Hosp., Maebashi, 14:Hematol., Chibaken Saiseikai Narashino Hosp., Narashino, 15:Hematol., Tokyo Medical Univ. Hachioji Medical Center, Hachioji, 16:Hematol., National Defense Medical College Hosp., Tokorozawa, 17:Pharmacy, Akita Univ. Hosp., Akita

Phase 1/2 study of Ponatinib in Japanese patients (Pts) with Ph+ leukemia: 3-year follow-up results

[演者] Kohei Kyo:1
[著者] Arinobu Tojo:2, Taiichi Kyo:3, Kazuhito Yamamoto:4, Hirohisa Nakamae:5, Naoto Takahashi:6, Yukio Kobayashi:7, Tetsuzo Tauchi:8, Shinichiro Okamoto:9, Koichi Miyamura:10, Kiyohiko Hatake:11, Hiromi Iwasaki:12, Itaru Matsumura:13, Noriko Usui:14, Tomoki Naoe:15, Heinrich Farin:16, Kazuma Ohyashiki:17
1:Hiroshima Red Cross and Atomic Bomb Survivors Hospital, Hiroshima, Japan, 2:The University of Tokyo, The Institute of Medical Science, Tokyo, Japan, 3:Itsukaichi Memorial Hospital, Hiroshima, Japan, 4:Aichi Cancer Center Hospital, Aichi, Japan, 5:Osaka City University Hospital, Osaka, Japan, 6:Akita University Hospital, Akita, Japan, 7:National Cancer Center Hospital, Tokyo, Japan, 8:Tokyo Medical University Hospital, Tokyo, Japan, 9:Keio University Hospital, Tokyo, Japan, 10:Japanese Red Cross Nagoya First Hospital, Aichi, Japan, 11:The Cancer Institute Hospital Japanese Foundation for Cancer Research, Tokyo, Japan, 12:Kyushu University Hospital, Fukuoka, Japan, 13:Kinki University Hospital, Osaka, Japan, 14:The Jikei University Daisan Hospital, Tokyo, Japan, 15:National Hospital Organization Nagoya Medical Center, Aichi, Japan, 16:ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA, 17:Tokyo Medical University Hospital, Tokyo, Japan

Successful dasatinib cessation after 2-year consolidation, the result of D-STOP trial

[演者] Takashi Kumagai (熊谷 隆志):1
[著者] Chiaki Nakaseko (中世古 知昭):2, Kaichi Nishiwaki (西脇 嘉一):3, Chikashi Yoshida (吉田 近思):4, Kazuteru Ohashi (大橋 一輝):5, Naoki Takezako (竹迫 直樹):6, Hina Takano (高野 弥奈):7, Yasuji Kozai (香西 康司):8, Tadashi Murase (村瀬 忠):9, Kosei Matsue (末永 孝生):10, Satoshi Morita (森田 智視):11, Junichi Sakamoto (坂本 純一):12, Hisashi Wakita (脇田 久):13, Hisashi Sakamaki (坂巻 壽):5, Koiti Inokuchi (猪口 孝一):14
1:Department of Hematology, Ome Municipal General Hospital, Tokyo Japan, 2:Department of Hematology, Chiba University Hospital, Chiba, Japan, 3:Clinical Oncology and Hematology, Jikei University, Kashiwa Hospital, Chiba, Japan, 4:Department of Hematology, Mito Medical Center, Higashiibarakigun, Japan, 5:Hematology Division, Komagome Hospital, Tokyo, Japan, 6:Dept. Hematol., National Hospital Organization Disaster Medical Center, Tachikawa, Japan, 7:Department of Hematology, Musashino Red Cross Hospital, Musashino, Japan, 8:Dept. Hematology, Tokyo Metropolitan Tama Synthesis Medical Center, Tokyo, Japan, 9:Dept. Laboratory Medicine, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan, 10:Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan, 11:Department of Biomedical Statistics and Bioinformatics, Kyoto University, Kyoto, Japan, 12:Tokai Central Hospital, Kakamigahara, Japan, 13:Div. Hematology and Oncology, Narita Red Cross Hosp., Narita, Japan, 14:Department of Hematology, Nippon Medical School, Tokyo, Japan

Interim analysis of the New TARGET study, the observational study for newly diagnosed CML in Japan

[演者] Yuichi Ishikawa (石川 裕一):1
[著者] Hitoshi Kiyoi (清井 仁):1, Ritsuro Suzuki (鈴木 律朗):2, Tatsuya Kawaguchi (川口 辰哉):2, Naoto Takahashi (高橋 直人):2, Kazuhito Yamamoto (山本 一仁):2, Kazunori Ohnishi (大西 一功):2, Masahiro Kizaki (木崎 昌弘):2, Tomoki Naoe (直江 知樹):2, Itaru Matsumura (松村 到):2
1:Dept. Hematol./Oncol., Nagoya University Graduate School of Medicine, Nagoya, Japan, 2:The Japanese Society of Hematology, New Target Study Committee

詳細検索